- Home
- CGTX vs COYA Comparison
CGTX vs COYA Comparison
Compare CGTX & COYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CGTX | COYA |
|---|---|---|
| Founded | 2007 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 132.4M | 126.6M |
| IPO Year | 2021 | 2022 |
Fundamental Metrics
Financial Performance| Metric | CGTX | COYA |
|---|---|---|
| Price | $1.54 | $5.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $2.88 | ★ $15.80 |
| AVG Volume (30 Days) | ★ 938.2K | 197.3K |
| Earning Date | 11-06-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,987,706.00 |
| Revenue This Year | N/A | $88.66 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.22 | $4.65 |
| 52 Week High | $3.83 | $8.29 |
Technical Indicators
Market Signals| Indicator | CGTX | COYA |
|---|---|---|
| Relative Strength Index (RSI) | 46.12 | 38.27 |
| Support Level | $1.46 | $5.25 |
| Resistance Level | $1.61 | $6.01 |
| Average True Range (ATR) | 0.11 | 0.32 |
| MACD | -0.02 | -0.08 |
| Stochastic Oscillator | 27.03 | 17.65 |
Price Performance
Historical ComparisonAbout CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.
About COYA Coya Therapeutics Inc.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.